Subject: Is Cerebroprotein Completely Useless? Short Answer No...
From: Derek from Research Radar <[email-masked]>
To: [email-masked]
Date: Sun, 3 May 2026 16:47:05 +0000
List-Id: <derekpruski.substack.com>

View this post on the web at https://derekpruski.substack.com/p/is-cerebroprotein-completely-useless

Read this first: Everything below is for research and educational purposes only. Nothing here is medical advice. Research peptides are NOT for human consumption.
Why I’m Writing This
If you’ve spent any time around research peptide vendors, you’ve seen “Cerebrolysin” sold as a freeze-dried powder in vials. You’ve probably also seen the real Ever Pharma version — pre-mixed liquid in glass ampules from Austria — and wondered why these two products look completely different, cost wildly different amounts, and ship through totally different channels.
Here’s the short answer: those research-vendor powder vials almost always aren’t actually Cerebrolysin. They’re Cerebroprotein, which is a related but distinct product with its own approval pathway and its own clinical research behind it.
The community consensus has quietly drifted toward “Cerebroprotein is just a cheap knockoff, don’t bother.” That framing is wrong, and it’s costing the research community access to a legitimately interesting compound class. This post walks through what Cerebroprotein actually is, what the research shows, and why it deserves to be evaluated on its own merits.
I already published a shorter primer on the topic — this is the deeper dive a lot of you have been asking for.
What Each One Actually Is
Cerebrolysin is a pig brain-derived peptide preparation made by Ever Pharma in Austria. It’s been around since the 1970s and is the product behind virtually every Western clinical trial you’ve read about for stroke, traumatic brain injury, vascular dementia, and Alzheimer’s. It comes as a pre-mixed liquid in glass ampules and doesn’t need to be reconstituted. Standardized concentration is 215.2 mg/mL.
Cerebroprotein (sometimes called Cerebroprotein Hydrolysate, CH-I, CH-II, or in Asian markets CEGI / Ignotin) is a separate product made primarily in China by established pharmaceutical companies including Hebei Zhitong Biopharmaceutical and Guangdong Long Fu Pharmaceutical. It’s also a brain-derived peptide hydrolysate, but it uses a different manufacturing process, which produces a slightly different peptide mixture. It comes as freeze-dried powder in vials and needs to be reconstituted.
Same general category. Different manufacturers. Different processes. Mechanistically very similar. Not identical products.
The Approval Most Researchers Don’t Know About
Here’s the part most of the Western research community misses: Cerebroprotein is NMPA-approved in China.
The NMPA (National Medical Products Administration) is China’s version of the FDA. Cerebroprotein hydrolysate has been used in Chinese hospitals for decades to support recovery from stroke, traumatic brain injury, dementia, memory loss, and attention issues. It went through its own regulatory pathway. It has its own published clinical research.
This is the part that changes the framing entirely. Cerebroprotein isn’t a research-only knockoff. It’s a real pharmaceutical product approved in one of the largest healthcare markets in the world. It just happens to be more accessible to researchers than Ever Pharma’s original.
How Brain-Derived Peptides Work (Plain English)
To understand why both products matter, you need to understand the basic mechanism — and it’s actually pretty intuitive.
Your brain produces its own growth and repair signals. Two of the most important ones are BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor). These act like maintenance crews — they keep neurons alive, help them form new connections, and protect them when they’re under stress.
The problem: BDNF and NGF are large proteins. They can’t cross the blood-brain barrier (the brain’s protective filter) on their own, and they break down within minutes once they’re in circulation. Simply having more of them in the body doesn’t actually get more of them into the brain.
Brain-derived peptide hydrolysates solve this by breaking down brain tissue into very small peptide fragments — small enough to actually cross into the brain. Once there, they don’t replace BDNF or NGF, but they mimic the signals those proteins send. The end result is similar: support for neuron survival, support for new connections, and protection against cellular stress.
Both Cerebrolysin and Cerebroprotein work on this same principle. The peptide profiles aren’t identical, but they’re hitting the same biological levers.
What the Research Actually Shows for Cerebroprotein
This is where Cerebroprotein has its own legitimate evidence base — separate from the Cerebrolysin trials. Let’s walk through it.
Protection against neuron death. CH-I (Cerebroprotein Hydrolysate-I) was studied in mouse models of vascular dementia, which is dementia caused by poor blood flow to the brain. CH-I reduced neuron death in the hippocampus — the brain’s memory center — and improved learning and memory performance. The mechanism involves a survival signaling pathway called PI3K/Akt, which essentially tells stressed neurons “don’t die yet” and shuts down the cellular self-destruct sequence.
Helping neurons grow new connections. CH-II was studied in PLOS One in 2019. It protected brain cells from oxygen deprivation (the lab version of a stroke), reduced damage from oxidative stress, and promoted neurite outgrowth — the technical term for neurons growing new branches and forming new connections. The authors specifically called CH-II a candidate worth advancing into early-phase Alzheimer’s trials.
Memory rescue in chemical amnesia models. The same CH-II study showed memory improvements in mice given scopolamine, a compound used to chemically impair memory in research. This is one of the standard tests for compounds with cognitive support potential, and CH-II passed it convincingly.
Slowing Alzheimer’s-related changes. A 2023 study in Frontiers in Pharmacology used the standard genetic Alzheimer’s mouse model (APP/PS1 mice). Cerebroprotein hydrolysate slowed neurodegenerative changes through a pathway called ferroptosis — a relatively new and increasingly important mechanism in Alzheimer’s research that involves iron-driven cell damage. This is one of the more mechanistically sophisticated pieces of work in the Cerebroprotein literature.
Repairing brain wiring after stroke. CH-I has been shown to protect white matter (the brain’s wiring) and support axonal plasticity (the ability of nerve fibers to adapt and repair) in late-stage post-stroke models.
Pediatric clinical research. Cerebroprotein hydrolysate has been studied in Chinese pediatric populations for developmental disorders, cerebral palsy, autism spectrum disorder, Asperger syndrome, and Rett syndrome. Reported outcomes include improvements in cognition, social skills, and motor function. This is one of the strongest separate use cases for Cerebroprotein specifically — it’s not just a Cerebrolysin substitute story.
The mechanisms identified for Cerebroprotein heavily overlap with what’s seen for Cerebrolysin: small peptides that get into the brain, support for neuron survival, protection from oxidative stress, and support for new neural connections.
The Practical Use Case for Cerebroprotein
This is where Cerebroprotein actually earns its place in the research community.
Stability. Freeze-dried powder stored properly stays stable for 1-3 years. Cerebrolysin ampules are pre-mixed liquid with a much tighter window once opened. For longer research protocols, the powder format is just more practical.
Shipping. Freeze-dried powder doesn’t require strict cold-chain shipping. Real Ever Pharma ampules coming into the US through proper channels is rare and expensive. Cerebroprotein in powder form is far easier to source through standard research vendors with COAs.
Cost. Cerebroprotein is dramatically cheaper per milligram than authentic Ever Pharma ampules. For multi-month protocols, this adds up significantly.
Flexibility. With freeze-dried powder, you control the reconstitution and the working concentration. With ampules, you’re locked into pre-mixed volumes (1, 2, 5, or 10 mL) at a fixed 215.2 mg/mL.
Real regulatory and clinical history. This isn’t an unstudied compound. It’s an NMPA-approved pharmaceutical product with peer-reviewed mechanism research and documented hospital use.
The Honest Caveats
Educational means honest. Here’s what Cerebroprotein is NOT.
It’s not the exact product from the Western trials. The hundreds of Cerebrolysin clinical trials used Ever Pharma’s specific proprietary product. You can’t assume Cerebroprotein replicates every outcome 1:1.
Source quality varies. “Cerebroprotein” is a product class with multiple manufacturers. Quality and peptide content can vary, which is why third-party COA verification matters.
Western researchers haven’t read most of the literature. The strongest Cerebroprotein-specific research comes out of Chinese groups. It’s legitimate, peer-reviewed work — it just doesn’t show up in the typical English-language reading list, so the evidence base feels thinner than it actually is.
Vendor labeling is often confusing. Many research vendors label powder vials as “Cerebrolysin” when what they actually have is Cerebroprotein. It matters that you know which one you’re working with.
The clinical study amounts don’t carry over directly. Cerebrolysin clinical research is reported in mL of pre-mixed liquid at 215.2 mg/mL. Cerebroprotein is in milligrams of freeze-dried powder. You have to do a quick conversion — covered in the next section.
How to Convert Study mL Amounts to Your Research Powder
Studies report Cerebrolysin amounts in mL of pre-mixed liquid. Your research powder is in milligrams. Here’s the simple way to correlate the two.
The key number to memorize: Pharmaceutical Cerebrolysin = 215.2 mg/mL. This is the concentration used in virtually every clinical study.
The math:
Study mL × 215.2 = mg equivalent
mg equivalent ÷ your concentration = your mL
Example using a real COA:
Vial contains 2,264 mg
Reconstituted in 10.52 mL of bac water
Concentration: 2,264 ÷ 10.52 = 215.2 mg/mL (matches pharma exactly)
Example study conversion:
Study used 5 mL/day → 5 × 215.2 = 1,076 mg equivalent
Study used 10 mL/day → 10 × 215.2 = 2,152 mg equivalent
Study used 30 mL → 30 × 215.2 = 6,456 mg equivalent
That’s it. Always work from YOUR vial’s actual COA numbers, not just label claims.
Why Cerebroprotein Is Underrated
Honest take after digging through this.
It has its own legitimate approval. NMPA approval in China and decades of clinical use. Not a research-only compound — an actual pharmaceutical product.
The mechanistic overlap is real. Both products deliver small, brain-penetrant peptides hitting overlapping pathways. The peptide mixtures aren’t identical, but the biology they engage is.
The Chinese research is real research. CH-I and CH-II have peer-reviewed data published in international journals.
The practical advantages are significant. Stability, shipping, cost, flexibility — these aren’t minor. They’re the reason most researchers can engage with this category at all.
What holds it back: it’s been incorrectly framed as a knockoff for years; the strongest literature is in journals English-only researchers don’t read; and vendor labeling confusion has made the whole category feel sketchy when the underlying product is legitimate.
Final Thoughts
Cerebroprotein gets dismissed because it doesn’t have a sexy origin story. It’s not the “real” Ever Pharma product. It comes from China. It’s labeled inconsistently across vendors. None of that is exciting.
What is exciting: it’s a legitimately approved pharmaceutical product with its own clinical and preclinical evidence, hitting the same biological mechanisms as one of the most studied neurotrophic compounds in the world, at a fraction of the cost and with much better stability and shipping logistics.
If brain-derived peptide hydrolysates are interesting to you as a research category — and the mechanisms genuinely are — then Cerebroprotein deserves to be evaluated on its own merits, not dismissed as a cheaper version of something else. It’s a different but related product, with its own approval, its own literature, and its own use case.
Whether the category translates into long-term outcomes is a question more research will answer over time. But the mechanisms, the existing safety data, and the multi-system effects already make Cerebroprotein worth knowing about deeply.
This is for research and educational purposes only. Research peptides are NOT for human consumption. Nothing in this post is medical advice.
References
Cerebroprotein Hydrolysate-I in vascular dementia (PI3K/Akt pathway): https://pmc.ncbi.nlm.nih.gov/articles/PMC8297406/ [ https://substack.com/redirect/5669e873-aa87-4757-8658-5adb22c20020?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Cerebroprotein Hydrolysate-II in Alzheimer’s models (PLOS One, 2019): https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222757 [ https://substack.com/redirect/2b97adb7-71be-4c6e-bf44-fe09f67acb4c?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Cerebroprotein hydrolysate in APP/PS1 Alzheimer’s mice (ferroptosis pathway), Frontiers in Pharmacology, 2023: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1177503/full [ https://substack.com/redirect/b3fbd1a0-dfac-401b-969e-2e2af72df0c2?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
CH-I in pediatric clinical use: https://pmc.ncbi.nlm.nih.gov/articles/PMC12439708/ [ https://substack.com/redirect/49ea2b68-a8fd-4c9f-9ef5-78803b299237?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Comparative pharmacology of Cerebrolysin and other peptide preparations (embolic stroke): Zhang L, Chopp M, Wang CY, et al. Journal of the Neurological Sciences. 2019.
Cerebrolysin clinical use review (30 years): Gavrilova SI, Alvarez A. Medicinal Research Reviews. 2020.
Cerebrolysin in stroke recovery review: Brainin M. Expert Review of Neurotherapeutics. 2018;18(8):681-687.
Chinese patent for cerebroprotein hydrolysate freeze-dried powder formulation: https://patents.google.com/patent/CN103142991A/en [ https://substack.com/redirect/11164a5f-9996-425d-a20d-d0c8f26f9d15?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOak15T1RBek5Dd2lhV0YwSWpveE56YzNPREkyT0RrNExDSmxlSEFpT2pFNE1Ea3pOakk0T1Rnc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LlJlMEJyMkFmdnRZSndHQUZJYmd5eG9fb2ZBUzgweTVjRXprM2IwdW1rcXciLCJwIjoxOTYzMjkwMzQsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc3ODI2ODk4LCJleHAiOjIwOTM0MDI4OTgsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.aRuqov45Mjwv45G_a3rgf4ygCDBtosuXytQH_EZzqAM?